Clinical Trial Update: A Clinical Study of Liposomal Doxorubicin Combined With Ifosfamide Second-line Treatment in Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document provides an update on a Phase 2 clinical study evaluating liposomal doxorubicin in combination with ifosfamide as second-line therapy for small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IFOSFAMIDE (IFOSFAMIDE)
• liposomal doxorubicin (doxorubicin liposomal)

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN